Connect with us

Technology

The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation”

Published

on

— Winners to be Announced on 11th June at the Prix Galien UK Awards Ceremony in London

LONDON, May 12, 2026 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2026 Prix Galien UK Award candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation.” Winners will be selected by a committee of distinguished scientific leaders and announced during the Prix Galien UK Awards Ceremony, on 11th June at the Natural History Museum in London. To learn more and secure your ticket to the event, please visit our website here.

“Annually, the Prix Galien UK awards remind us that innovation in life sciences is not just about discovery, it’s about impact,” said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee. “It is a privilege to return to this year’s Prix Galien UK Awards to recognise the latest cohort of innovators who embody the UK’s unwavering commitment to transforming scientific breakthroughs into better outcomes for patients, worldwide.”

The Prix Galien UK Awards Committee will be evaluating the innovation demonstrated throughout each product’s scientific development, clinical application, and utility. Further consideration is given to the insights it has advanced in biomedical science and the product’s tangible impact on human health.

“The Prix Galien stands as a global tribute to the power of human ingenuity in advancing health across the world,” said Bruno Cohen, Chairman of The Galien Foundation. “We look forward to continuing to honour those whose vision and dedication push the boundaries of medical progress as we approach the 2026 Prix Galien UK Awards.”

The 2026 Prix Galien UK Award Candidates are as follows:

Best Biotechnology Product (Candidates) 

Company

Product

Autolus Ltd

Aucatzyl

Kristal Biotech

Vyjuvek

Volition

Nu.Q® Vet Cancer Test

Best Digital Health Solution (Candidates) 

Company

Product

August International Limited

AI-Powered Real-time Telehealth Scheme

Evaxion

AI-Immunology™ platform

Evinova

Unified Trial Solution

Gulsine ltd.

A2P2 Platform

HARLEYDOC

HARLEYDOC APP

House of Possibility Limited
(TRADING AS RAPID TAPPING)

Rapid Tapping®

Otsuka Pharmaceuticals (UK) Ltd

Rejoyn

Perspectum

CoverScan

SökerData

SökerScan

Viscera Technologies Ltd

Quantico

Best Medical Technology (Candidates) 

Company

Product

MiniMed

MiniMed Go Smart MDI system

Novocure UK Limited

Optune Gio

Nyxoah SA

Genio

Smith & Nephew Medical Ltd.

RENASYS EDGE

THERMOTRAUMAPORT LTD

THERMOTRAUMAPORT

U-test diagnostics

U-test @ Home

Best Pharmaceutical Product (Candidates) 

Company

Product

AbbVie UK

Elahere®

Aventis Pharma (SANOFI)

TZIELD

Blueprint Medicines, a Sanofi company

Gilead Sciences Ltd

Sunlenca/Yeytuo

Incyte Biosciences UK Ltd

Opzelura® (ruxolitinib) 15 mg/g cream

Novartis Pharmaceuticals UK

Iptacopan▼

PhytoQuest Limited

Q-actin®

Servier Laboratories Ltd

Voranigo▼

Shionogi

Fetcroja

ViiV Healthcare

Apretude

Best Public Sector Innovation (Candidates) 

Company

Product

BioDundee

BioDundee’s Life Sciences and Healthcare Innovation Ecosystem

University College London Centre for Digital
Public Health in Emergencies (UCL dPHE)

Digital platform for vector-borne diseases (VBD) surveillance and early warning in Brazil and Madeira

University of Glasgow

Intensive low-calorie weight management programme to induce type 2 diabetes remission

University of Liverpool

Liverpool’s COVID-19 Trio: ISARIC (clinical characterisation), SMART (testing) and AGILE (trials)

University of Liverpool and Liverpool University
Hospitals NHS Foundation Trust

LDIR Tech

Well Cool Clothing Ltd

Well Cool Patient Wear

Best Health Equity Innovation (Candidates) 

Company

Product

Agios Pharmaceuticals, Inc.

Clinical Trials Designed with Patients, for Patients: RISE UP Sickle Cell Disease Clinical Program

Eli Lilly as the Sponsor in collaboration with 
North West e-Health, Health Innovation
Manchester and the University of Manchester

An open-label, pragmatic clinical trial in a UK real world setting in people living with obesity

HARLEY of LONDON

Harley Wellness Dollar Empowering Community Health, Wellness and Lifestyle

National Institute for Health and Care
Excellence (NICE)

NICE technology appraisal guidance (TA1044) for exagamglogene autotemcel (exa-cel) for
treating severe sickle cell disease in people 12 years and over. TA1044

Nuffield Department of Primary Care
Health Sciences University of Oxford

Centre for Research Equity through pharmacy, communities and healthcare

ProFactor Pharma

Affordable recombinant Factor VIII

Quercis Pharma AG

Kinisoquin™

Sisters of Support CIC

Sisters of Support

The Drug Discovery Unit, University of Dundee

Drug Discovery for Neglected Infectious Diseases

University of Glasgow

Enabling equitable access to lifesaving rabies post-exposure prophylaxis

The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since its inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK’s leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.

During the ceremony, the 2026 Prix Galien UK Lifetime Achievement Award will be bestowed upon Dame Kate Bingham, Former Chair of the UK Government’s Vaccine Taskforce. The keynote address will be delivered by Dr John-Arne Røttingen, MD, PhD, CEO, Wellcome; Committee Member, Prix Galien Bridges.

Prix Galien UK Awards Committee 2026

Professor Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics
Committee Chair

Professor Jane ADAM
Honorary Professor, University of Exeter, Consultant Radiologist, St George’s Hospital London and former Chair Technology appraisal committee, NICE

Professor Bruce CAMPBELL
Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor, Exeter

Alison CAVE, PhD
Chief Safety Officer, Medicines and Healthcare products Regulatory Agency (MHRA)

Professor Jesse DAWSON
Professor of Stroke Medicine at School of Cardiovascular and Metabolic Health in the College of Medical, Veterinary and Life Sciences at the University of Glasgow; Consultant Physician in the Queen Elizabeth University Hospital, Glasgow

Doctor Stephanie KUKU
Chief Knowledge Officer – Conceivable Life Sciences, Senior Consultant – Hardian Health, Board Trustee – The Kings Fund, Honorary Senior Research Fellow, UCL

Professor Sudhesh KUMAR, OBE
Vice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)

Professor Andrew MORRIS, CBE
Director, Health Data Research UK & Professor of Medicine and Vice Principal Data Science, University of Edinburgh

Professor Sharon PEACOCK, CBE
Master of Churchill College Cambridge

Professor Duncan RICHARDS
Professor of Clinical Therapeutics, University of Oxford

Doctor Lauren WALKER
Professor of Clinical Pharmacology & Therapeutics, University of Liverpool

Professor Dame Moira WHYTE
Sir John Crofton Professor of Respiratory Medicine, University of Edinburgh

About The Galien Foundation 
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates in 16 countries across Africa, Europe, the United States and the UK. Expansion is currently underway in South Korea, Japan, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognises up to three individuals for specific discoveries, the Prix Galien honours the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

See the UK Hall of Fame: https://infogram.com/prix-galien-uk-since-1990-1hnp27e0qqyzn4g.

Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060

Media Contact (Global):
Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243

Logo – https://mma.prnewswire.com/media/2592709/The_Galien_Foundation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-2026-prix-galien-uk-award-candidates-for-best-biotechnology-product-best-digital-health-solution-best-medical-technology-best-pharmaceutical-product-best-public-sector-innovation-and–302768995.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

JK Tech Brings Agentic AI to the Forefront at Two Major Industry Events

Published

on

By

NEW YORK, May 12, 2026 /CNW/ — JK Tech, a global AI and Data solutions provider has announced its participation in two premier U.S. industry forums- HFS Spring Summit and Datos Regional Property & Casualty Insurance Forum, underscoring its commitment to helping U.S. enterprises accelerate AI-led transformation with measurable business outcomes. The company will showcase how its AI-first portfolio is enabling enterprises across industries to move beyond experimentation and operationalize intelligence at scale.

As U.S. businesses grapple with growing complexity, disconnected systems, and mounting pressure to do more with less, JK Tech is stepping in with a clear message: intelligence shouldn’t sit in silos- it should be adaptable and agile.

At the HFS Spring Summit, the spotlight falls on JIVA, JK Tech’s enterprise-ready Agentic AI platform, alongside its Enterprise Ontology framework. Together, these solutions help organizations build AI systems that are contextual, governed, and explainable — not just powerful. The goal is faster decisions, modernized service delivery, and meaningful transformation across enterprise operations. Retail and commerce leaders will also get a look at Orbiee, JK Tech’s conversational commerce platform, which brings intent-aware, emotionally intelligent engagement to customer interactions, driving more personalized experiences, stronger loyalty, and better conversion outcomes.

At Datos Insights, JK Tech shifts focus to the insurance sector, showing how the same AI-led approach can help insurers modernize underwriting, claims, customer service, and core operations. The emphasis is on contextual intelligence, responsible AI, and automation that delivers real, measurable results, not just technological novelty.

Across both events, JK Tech’s core argument is consistent: the future of enterprise AI isn’t about isolated pilots. It’s about systems that work together, at scale, in the real world.

“U.S. enterprises are no longer looking for AI that simply informs, they need AI that acts,” said Deepak Srinivasan, Chief Solutions Officer at JK Tech. “We’re helping organizations move from disconnected experimentation to intelligent, outcome-driven execution by combining agentic AI, trusted enterprise data, and domain context into systems that deliver measurable business value.”

By participating in both forums, JK Tech is reinforcing its role as a reliable transformation partner for U.S. enterprises.

About JK Tech

JK Tech is a GenAI-focused data and AI services organization empowering enterprises across Retail, CPG, and Insurance. Through deep expertise in data platforms, AI orchestration, and enterprise transformation and flagship solutions such as JIVA, its Gen AI Orchestrator, and Orbiee, its conversational commerce platform, JK Tech helps global organizations unlock actionable insights, operational excellence, and sustainable growth. To learn more, visit www.jktech.com. Find JK Tech on X, LinkedIn.

Logo: https://mma.prnewswire.com/media/2088130/JK_Tech_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/jk-tech-brings-agentic-ai-to-the-forefront-at-two-major-industry-events-302769332.html

SOURCE JK Tech

Continue Reading

Technology

Instacart Joins Collaborative for Healthy Rural America (CHRA) to Expand Access to Nutrition and Essential Goods

Published

on

By

The collaboration supports states advancing CMS Rural Health Transformation initiatives with technology-enabled implementation, AI-driven virtual primary care, and integrated access to food and community-based services

WASHINGTON, May 12, 2026 /PRNewswire/ — The Collaborative for Healthy Rural America (CHRA) today announced that Instacart has joined the collaborative, expanding its ability to help states address chronic disease and improve health outcomes by integrating access to nutritious food and essential goods into coordinated care delivery models. The addition of Instacart further enhances the collective approach to longitudinal, AI-enabled primary care and community engagement advanced by Deloitte Consulting LLP, Lumeris, Nuna, Teladoc Health, and Unite Us.

Instacart joins CHRA to help rural communities address chronic disease through better nutrition access.

The addition of Instacart comes as states begin implementing new Rural Health Transformation (RHT) initiatives with funding from the Centers for Medicare & Medicaid Services (CMS). State teams are pivoting from outlining five year plans to operationalizing and demonstrating near term progress.

“Expanding access to nutritious food is one of the most powerful things we can do to improve health outcomes,” said Sarah Mastrorocco, Vice President and General Manager of Health at Instacart. “Through Instacart Health, we’re working to use delivery of nutritious groceries as a tool to help Americans prevent and manage chronic conditions. By joining CHRA, we have an opportunity to integrate our capabilities into care delivery models further, helping states address the root causes of disease while improving access, engagement, and outcomes in rural communities.”

With approximately $10 billion in first-year RHT funding awarded nationally, states are advancing implementation within defined timelines while strengthening workforce capacity, governance structures, and performance management capabilities required under CMS cooperative agreements. As Year 2 funding decisions are informed by Year 1’s progress, states are focused on demonstrating early implementation while building durable systems designed to be sustained beyond federal funding.

The CHRA was formed to support state-directed implementation of CMS’s RHT program. CHRA brings together private sector experience and proven, interoperable technology to help states move rapidly from planning to execution. By combining advanced analytics, virtual care, interoperable data platforms, and closed-loop referrals for community-based service integration, CHRA enables states to operationalize complex rural health transformation initiatives at scale, reducing the need for each state to build new capabilities from scratch.

CHRA’s founding collaborators include Deloitte, Lumeris, Nuna, Teladoc Health, and Unite Us. The addition of Instacart to the collaborative helps states expand access to nutritious foods and everyday essentials to address chronic disease and related needs. Together, CHRA represents a comprehensive operating model that is intentionally aligned with CMS expectations, reducing the need for health systems to assemble and manage disparate components independently

Built Around State-Identified Challenges

CHRA conducted a detailed review of publicly available state RHT plans to understand the challenges states themselves have identified as most urgent. While needs vary by geography, four themes consistently emerged across plans.

1. Infrastructure Misalignment in Rural Health Systems

States across the country describe a structural mismatch between legacy rural health infrastructure, declining populations, and fee-for-service payment models. The State of Wyoming notes that rural hospitals face “high fixed costs and low patient volume,” while still needing to maintain emergency capacity. Vermont reports that more than half of hospitals operate at a loss due to low volume, workforce shortages, aging infrastructure, and high fixed operating costs. Illinois highlights large inpatient facilities that are rarely fully occupied, undermining financial viability. Across the country, rural health transformation plans converge on the need for alternative payment models, redesigned delivery systems, flexible workforce strategies, and technology-enabled care to create sustainable models of care.

How CHRA can help states:
CHRA supports states in exploring and operationalizing redesigned care delivery models better suited to low volume, high fixed cost environments such as those intended to be addressed by RHT initiatives. At the core of this approach is the transformation of primary care from episodic, site-based care to continuous, coordinated, and population-driven models that better meet the needs of rural communities.

Through interoperable service models, built to complement existing EHR and HIE systems, CHRA has the opportunity to support beneficiary identification, outreach, virtual and in-person care, care coordination, and outcomes tracking. For instance, CHRA member Lumeris, powered by Tom™, enables primary care teams to operate with greater reach and efficiency—proactively managing patient populations, closing care gaps, and extending care beyond traditional settings.

These supports, alongside virtual care delivery through Teladoc Health’s network of providers and Nuna’s AI-native patient engagement mobile app, introduce a more scalable, prevention-oriented primary care model that aligns payment, workforce capacity, and service delivery with population needs while relieving rural facilities of the burden of sustaining underutilized infrastructure on their own.

2. Gaps in Preventive Care Delivery

States report persistent barriers to preventive services. The State of Iowa cites gaps in early detection and prevention. The State of Maine highlights limited capacity for population-level screening and outreach. Workforce shortages, transportation challenges, and infrastructure constraints limit consistent access to preventive care.

How CHRA can help states:
CHRA leverages population data, predictive analytics, and AI-supported outreach to help states identify priority populations and close preventive care gaps. Unite Us’ Self Sufficiency Score establishes a benchmark, connecting rural residents to medical, behavioral, and community support services via an integrated closed-loop referral and payment platform.

Utilizing the Tom™ platform, CHRA extends prevention beyond episodic care by continuously monitoring patient needs, proactively identifying rising risks, and engaging individuals between visits through timely, personalized outreach. By orchestrating interventions across care teams and community resources, Tom helps ensure preventive actions happen earlier, before conditions escalate, enabling more consistent care, improving health outcomes, and reducing downstream costs associated with avoidable complications.

3. High Burden of Chronic Disease

Chronic disease management is a central concern across state plans. The State of Nevada identifies heart disease, cancer, and chronic lower respiratory disease as leading causes of death. The State of New Jersey emphasizes the need to modernize identification and access to treatment. The State of New Mexico calls for expanded specialty access and evidence-based models, while the Commonwealth of Virginia highlights access to nutrition as a root cause of poor health.

How CHRA can help states:
CHRA helps states more effectively prevent and slow chronic disease by enabling continuous, data-driven management of patient populations. Tom identifies rising-risk individuals, closes care gaps, and proactively engages patients between visits—supporting adherence, surfacing unmet needs, and coordinating timely interventions across care teams. Through CHRA, partners like Teladoc Health that integrate Instacart Health tools, will extend this model by enabling interventions that deliver personalized, clinically aligned nutrition support directly to patients, addressing key drivers of chronic conditions. Using Instacart Health Fresh Funds, stipends for nutritious food, and Care Carts, which allow organizations to order groceries on behalf of others, partners can build programs that address the needs of rural communities. Together, this approach tackles root causes, improves long-term disease management, and reduces avoidable emergency utilization.

4. Workforce Shortages and Provider Access

States consistently cite challenges with recruiting and retaining providers. The State of Ohio reports service lines at risk due to workforce shortages. The State of Nevada ranks near the bottom nationally in physician availability. The State of Georgia reports that most counties are facing a shortage of OBGYNs or pediatricians. Nationally, more than 190 rural hospitals have closed since 2005, with hundreds more at risk, according to the North Carolina Rural Health Research Program.

How CHRA can help states:
CHRA supports Primary Care as a Service (PCaaS) models using solutions like Lumeris’ Tom™ platform, which provides the backbone technology that extends provider capacity through AI-assisted triage, virtual care, and team-based workflows. Deloitte provides cross-platform interoperability and data integration services, grounded in decades of experience supporting states. And Teladoc Health has the largest nationwide network of virtual care providers including licensed clinicians, therapists, and health coaches, and can help patients access care quickly amid shortages or barriers to care. These approaches aim to expand access while keeping local providers at the center of care and reducing burnout. 

Looking Ahead

States will report Year 1 progress to CMS in October 2026. Those that demonstrate measurable improvements in access, utilization, and sustainability will be positioned for continued funding. CHRA’s role is to support states in achieving early momentum while building sustainable rural health systems.

About CHRA

The Collaborative for Healthy Rural America (CHRA) is a coalition of organizations supporting state led rural health transformation initiatives through coordinated, implementation focused support across care delivery, data, community integration, and sustainability.

Learn more: https://healthyruralamerica.org

View original content:https://www.prnewswire.com/news-releases/instacart-joins-collaborative-for-healthy-rural-america-chra-to-expand-access-to-nutrition-and-essential-goods-302768800.html

SOURCE Lumeris

Continue Reading

Technology

Branford Castle-Backed Lafayette Instrument Acquires Sutter Instrument Corp.

Published

on

By

Significantly Expands Its Life Sciences Instrumentation Product Offerings

NEW YORK and BOCA RATON, Fla., May 12, 2026 /PRNewswire/ — Lafayette Instrument, LLC, a leading global manufacturer of scientific instrumentation equipment for the life sciences, polygraph and human evaluation markets, today announced that it has acquired Sutter Instrument Corp. Terms of the transaction were not disclosed.

Lafayette is a portfolio company of North American-focused private equity firm Branford Castle Partners. Sutter marks the fifth bolt-on investment for Lafayette since being acquired by Branford Castle’s Fund II in 2021.

With the acquisition of Sutter, Lafayette reinforces its commitment to provide unparalleled support to the life science research community through experiment-focused software and instrumentation. Sutter is a leading provider of precision scientific instruments used by universities and research institutions globally for electrophysiology, neuroscience, and other related life sciences research.

Benjamin Mangrich, CEO of Lafayette Instrument, said, “Sutter Instrument has been a global leader in instrumentation supporting cellular research and electrophysiology for over 50 years. The company’s strong product portfolio, deep technical expertise, and commitment to customer success make them a natural complement to Lafayette Instrument’s Life Science portfolio.”

Ceon Francis, Managing Director at Branford Castle, stated, “This acquisition strengthens Lafayette’s platform and broadens its product offering to better serve a growing base of life sciences customers who demand the latest tools and technology. We are excited to collaborate with management as we continue to build on the company’s momentum and drive long-term growth.”

Branford Castle was advised by its legal counsel Akerman LLP, and RSM served as its accounting/tax advisor. EC M&A acted as financial advisor and Donahue Fitzgerald LLP acted as legal advisor to Sutter. Byline Bank is providing senior debt financing and Brookside Capital Partners is providing mezzanine debt financing for the transaction.

ABOUT BRANFORD CASTLE PARTNERS
Branford Castle is a private market investor focused on lower middle-market investments, with more than 35 years of helping to grow businesses. The Firm typically makes control investments in companies with up to $15 million of EBITDA and a leadership position in a niche industry. Branford Castle prides itself on the strong relationships it develops with its portfolio company managers. Branford Castle has particular expertise in industrials/specialty manufacturing, consumer products, business services and logistics.

ABOUT LAFAYETTE INSTRUMENT
Lafayette Instrument Company has over 75 years of experience engineering and manufacturing high-quality scientific instrumentation and data acquisition equipment for disciplines such as biology, neuroscience, pharmaceutical and medical research, physical therapy and rehabilitation, security, and law enforcement. Lafayette is positioned at the forefront of neuroscientific discovery, human evaluation, and credibility assessment.

Media Contact:
LLYC
Jennifer Hurson
Jennifer.hurson@llyc.global
Or
Joanne Lessner
Joanne.lessner@llyc.global

 

View original content:https://www.prnewswire.com/news-releases/branford-castle-backed-lafayette-instrument-acquires-sutter-instrument-corp-302769068.html

SOURCE Branford Castle Partners

Continue Reading

Trending